An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma (DLBCL).
Stable disease or better for at least 3 months on most recent treatment
Have not received any chemotherapy, radiation therapy, major surgery, or any other investigational therapy for at least 4 weeks prior to entry in this study
Adequate blood testing, liver, and kidney function as required by the study.
Eligible subjects will allow tissue samples to be examined and stored.
Patient has been treated with other investigational agents with a similar anti-tumor mechanism.
Patient should not have failed more than 3 prior treatment regimens.